Dupixent Lymphoma Lawsuits Centralized: What the New MDL Means

Dupixent Lawsuits Now Share One Federal Courtroom

Federal lawsuits alleging a connection between Dupixent (dupilumab) and cutaneous T-cell lymphoma have been centralized into a single multidistrict litigation. The MDL was created in June 2026 and assigned to the U.S. District Court for the District of New Jersey. Sanofi and Regeneron are named as defendants.

If you or a family member used Dupixent for eczema or atopic dermatitis and later received a lymphoma diagnosis, this news may raise more questions than it answers. This post explains what centralization is, what it is not, and what the lawsuits allege at this early stage.

This litigation is at its beginning, and very little has been established. The claims described below are allegations that no court has yet tested.

What the Judicial Panel Actually Decided

Centralization decisions come from the Judicial Panel on Multidistrict Litigation, a group of federal judges who decide whether similar cases filed in different districts should be handled together before trial. The Panel’s authority comes from a federal statute, 28 U.S.C. § 1407, which allows cases to be transferred when they share common questions of fact and coordination would promote convenience and efficiency.

That is the whole of the Panel’s role. An order centralizing cases is not a finding that Dupixent caused anyone’s cancer. The Panel does not weigh scientific evidence, decide whether a warning was adequate, or evaluate any individual claim. It decides where and how pretrial work happens.

In practical terms, centralization usually means the following:

• One judge oversees discovery, such as document production from the manufacturers and depositions of witnesses
• Disputes about expert testimony can be resolved once rather than in many separate courtrooms
• Plaintiffs’ attorneys typically coordinate through leadership committees appointed by the court
• Each case remains an individual lawsuit rather than a class action

The Two Allegations the Lawsuits Plead

Coverage of the Dupixent litigation often focuses on one idea, but the complaints generally advance two distinct allegations. An account that includes only the first is incomplete.

The first allegation is that Dupixent may cause or accelerate the development of a cutaneous T-cell lymphoma in some patients. Plaintiffs contend that the manufacturers did not adequately warn patients and prescribers about this possible risk.

The second allegation is that Dupixent may mask the early symptoms of a lymphoma the patient already had. Under this theory, improvement in skin symptoms could make an existing lymphoma look like eczema responding to treatment, which plaintiffs allege delayed a correct diagnosis and the start of cancer care.

Both allegations are under examination in active litigation. Neither has been established as a proven medical mechanism, and the manufacturers have not been found liable for anything.

Why a Diagnosis Before Dupixent Is Not Automatically Disqualifying

Because of the second allegation, the timing of a diagnosis matters differently than many people assume. Someone diagnosed with a cutaneous T-cell lymphoma before starting Dupixent, or whose lymphoma is believed to have been present before treatment, is not automatically excluded from the kinds of claims being pleaded.

Clinicians have long recognized that early mycosis fungoides, the most common form of cutaneous T-cell lymphoma, can resemble eczema or other common rashes. The National Cancer Institute provides patient information about mycosis fungoides and Sézary syndrome, including how they are diagnosed and treated.

Whether a particular person’s history fits either allegation depends on medical records, biopsy results, and the sequence of treatment and diagnosis. That question calls for a careful review of the records rather than a self-assessment.

Conditions Referenced in the Litigation

The lawsuits center on cutaneous T-cell lymphomas, a group of cancers that begin in T-cells and affect the skin. The diagnoses most often referenced include:

• Mycosis fungoides, which may appear as patches, plaques, or tumors on the skin
• Sézary syndrome, a form that involves the blood as well as widespread skin redness
• Other cutaneous T-cell lymphomas diagnosed during or after Dupixent treatment

Anyone with questions about their own diagnosis should speak with their oncologist or dermatologist. Legal research is not a substitute for medical care, and no one should stop or change a prescribed medication without first talking to their doctor.

What Centralization Does Not Change

Centralization changes where pretrial work happens, but it leaves several things that matter to individual patients untouched.

• Deadlines still apply. Statutes of limitations are set by state law, and a pending MDL generally does not pause them for people who have not yet filed.
• Each claim is individual. A person’s medical history, diagnosis, and treatment timeline are evaluated on their own.
• No outcome is predetermined. Cases that are not otherwise resolved may later be sent back to their original courts for trial.
• Later rulings shape the path. Decisions on expert testimony and legal defenses typically come later and can significantly affect how the litigation proceeds.

What Usually Happens Next in an Early-Stage MDL

In most MDLs, the early months are spent organizing the litigation. The court appoints plaintiff leadership, sets schedules, and establishes how records and evidence will be exchanged. Later stages commonly include expert discovery, rulings on whether scientific testimony meets the standards for admissibility, and in some litigation, the selection of bellwether cases for trial.

No one can responsibly predict how long this will take or how it will end. Information about the federal court system is available through the federal judiciary, and patients can review drug safety information published by the FDA.

Records Worth Gathering Now

If you are considering having your situation reviewed, some documents can help clarify your timeline. You do not need all of them before reaching out, because many can be requested on your behalf.

• Pharmacy or insurance records showing when you started and stopped Dupixent
• Dermatology records describing your eczema or atopic dermatitis before and during treatment
• Skin biopsy and pathology reports
• Oncology records reflecting your lymphoma diagnosis and staging
• Any notes about skin symptoms that changed, worsened, or failed to improve

Families considering a claim on behalf of a loved one who has died may also want to locate the death certificate and any estate documents.

Take the Next Step

A lymphoma diagnosis is hard enough on its own, and trying to understand a new federal litigation at the same time can feel overwhelming. You can learn more on our Dupixent lymphoma practice page.

Start your free case review to talk with our team about your Dupixent use, your diagnosis, and the timeline of your care. The review carries no obligation, and it does not commit you to filing anything.